Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Receivables (2020 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Change in Receivables for 6 consecutive years, with -$979000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Change in Receivables fell 141.96% to -$979000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was -$2.1 million, a 234.45% decrease, with the full-year FY2025 number at -$2.1 million, down 234.45% from a year prior.
  • Change in Receivables was -$979000.0 for Q2 2025 at Fulcrum Therapeutics, up from -$1.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $2.5 million in Q1 2022 to a low of -$3.4 million in Q4 2022.
  • A 5-year average of -$29500.0 and a median of -$59500.0 in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: tumbled 10851.61% in 2022, then skyrocketed 1840.79% in 2024.
  • Fulcrum Therapeutics' Change in Receivables stood at -$31000.0 in 2021, then crashed by 10851.61% to -$3.4 million in 2022, then surged by 98.73% to -$43000.0 in 2023, then tumbled by 3527.91% to -$1.6 million in 2024, then skyrocketed by 37.24% to -$979000.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Change in Receivables are -$979000.0 (Q2 2025), -$1.1 million (Q1 2025), and -$1.6 million (Q4 2024).